Company Pharmaron Beijing Co., Ltd.

Equities

300759

CNE100003JW4

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Group companies

Sector

Sales per Business

Sales per region

Ratings for Pharmaron Beijing Co., Ltd.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
18.17 ^CNY	-1.57%		-4.37%	-37.30%

Apr. 08	Pharmaron Partners Seven Firms to Float 2 Billion Yuan Fund	MT
Mar. 28	Pharmaron's 2023 Profit, Revenue Rise; Misses Estimates	MT

Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows:

- laboratory services (61.3%);

- development and production of chemical processes and formulations (23.5%);

- clinical research services (12.8%);

- other (2.4%);

Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).

CNY in Million	2022	Weight	2023	Weight	Delta
Laboratory Services 57.7 %	6,245	60.8 %	6,660	57.7 %	+6.65%
Chemical and Formulation Process Development and Production Services 23.5 %	2,407	23.4 %	2,711	23.5 %	+12.64%
Clinical Research Services 15.1 %	1,394	13.6 %	1,737	15.1 %	+24.66%
Macromolecule and Cell and Gene Therapy Services 3.7 %	195	1.9 %	425	3.7 %	+117.76%
Others 0.0 %	26	0.3 %	5	0.0 %	-82.39%

CNY in Million	2022	Weight	2023	Weight	Delta
North America 64.1 %	6,644	64.7 %	7,401	64.1 %	+11.39%
China 17.1 %	1,881	18.3 %	1,975	17.1 %	+5.02%
Europe 16.0 %	1,483	14.4 %	1,844	16.0 %	+24.35%
Asia (Excluding Mainland China) 2.3 %	233	2.3 %	269	2.3 %	+15.23%
Others 0.4 %	25	0.2 %	49	0.4 %	+95.40%

Managers	Title	Age	Since
Bei Zheng FOU	Founder	57	04-06-30
Xiao Qiang Lou FOU	Founder	55	04-06-30
Bo Liang Lou CEO	Chief Executive Officer	60	04-06-30
Ke Xin Yang CHM	Chairman	62	04-06-30
Cheng Zong Li DFI	Director of Finance/CFO	46	07-12-31
Hua Yang CTO	Chief Tech/Sci/R&D Officer	62	07-06-30
Lan Zhang BRD	Director/Board Member	42	06-04-04
Yi Qun Shi PRN	Corporate Officer/Principal	-	13-03-31
Bhaskar Reddy Guntoori PRN	Corporate Officer/Principal	-	11-06-30
Bin He PRN	Corporate Officer/Principal	-	07-01-01

Members of the board	Title	Age	Since
Kwan Hung Tsang BRD	Director/Board Member	60	19-08-14
Jia Qing Li BRD	Director/Board Member	51	16-10-26
Bo Liang Lou CEO	Chief Executive Officer	60	04-06-30
Xiao Qiang Lou FOU	Founder	55	04-06-30
Bei Zheng FOU	Founder	57	04-06-30
Qi Lin Zhou BRD	Director/Board Member	67	22-09-22
Jian Yu BRD	Director/Board Member	50	20-07-22
Lan Zhang BRD	Director/Board Member	42	06-04-04
Bai Feng Hu BRD	Director/Board Member	43	17-10-12
Li Hua Li BRD	Director/Board Member	60	16-10-26

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	201,024,750	0	0	50.56 %
Stock B	1	1,500,066,956	859,998,575 ( 57.33 %)	14,209,784 ( 0.9473 %)

Name	Equities	%	Valuation
UP FINTECH HOLDING LIMITED 5.124 %	15,452,081	5.124 %	19 M ¥
Matthews International Capital Management LLC 4.372 %	13,184,700	4.372 %	16 M ¥
Shenzhen Gemboom Investment Mgmt Co.,Ltd 2.141 %	6,456,333	2.141 %	8 M ¥
Huatai-PineBridge Fund Management Co., Ltd. 2.135 %	6,437,400	2.135 %	8 M ¥
BlackRock Fund Advisors 1.905 %	5,744,250	1.905 %	7 M ¥
GF Fund Management Co., Ltd. 1.270 %	3,830,858	1.270 %	5 M ¥
Fullgoal Fund Management Co., Ltd. 1.149 %	3,463,340	1.149 %	4 M ¥
GIC Pte Ltd. (Investment Management) 1.135 %	3,422,023	1.135 %	4 M ¥
Citic Securities Co., Ltd. (Invt Port) 0.7765 %	2,341,350	0.7765 %	3 M ¥
Bosera Asset Management Co., Ltd. 0.7406 %	2,233,275	0.7406 %	3 M ¥

Name	Equities	%	Valuation
Xiao Qiang Lou 79.43 %	51,041,250	79.43 %	144 M ¥

Name	Equities	%	Valuation
CITIC M&A Fund Management Co. Ltd. 21.54 %	306,046,464	21.54 %	863 M ¥
Bo Liang Lou 12.70 %	180,496,500	12.70 %	509 M ¥
Xiao Qiang Lou 7.085 %	100,675,076	7.085 %	284 M ¥
Zhong Ou Asset Management Co., Ltd 6.757 %	96,015,339	6.757 %	271 M ¥
Bei Zheng 2.654 %	37,706,986	2.654 %	106 M ¥
Legend Capital Co. Ltd. 2.178 %	30,941,457	2.178 %	87 M ¥
Hwabao WP Fund Management Co., Ltd. 1.752 %	24,894,624	1.752 %	70 M ¥
GF Fund Management Co., Ltd. 1.623 %	23,059,716	1.623 %	65 M ¥
China Merchants Fund Management Co., Ltd. 1.366 %	19,412,385	1.366 %	55 M ¥
Fullgoal Fund Management Co., Ltd. 1.222 %	17,357,956	1.222 %	49 M ¥

Pharmaron Beijing Co., Ltd.

8/F, Building 1 6 Taihe Road

100176, Beijing

+86 10 5733 0087

http://www.pharmaron.cn

address Pharmaron Beijing Co., Ltd.(300759)

Name	Category and Sector
Pharmaron (Hong Kong) International Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

18.17 CNY

Average target price

25.3 CNY

Spread / Average Target

+39.26%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
PHARMARON BEIJING CO., LTD.	-37.30%	4.07B
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+46.73%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research